CD8A and neoplasm: Interestingly, 2 of the 12 patients demonstrated increased PD-L1 expression following ONCOS-102 administration and developed systemic anti-tumor immunity, made evident by melanoma associated antigen 3 (MAGE-A3)-specific CD8+ T cells and New York esophageal squamous cell carcinoma 1(NY-ESO-1)-specific CD8+ T cells [67,68].